Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Michael Schuster

Showing results (121-130 of 145) with videos related to

Pageof 15
Sort By:
Journal of Clinical Anesthesia|August 14, 2025
Removal of EpCAM-positive tumor cells during intraoperative blood salvage- A pivotal multicenter clinical study (REMOVE)Patrick Meybohm, Suma Choorapoikayil, Sebastian Zinn, et al.
The New England Journal of Medicine|March 1, 2002
Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemiaHagop Kantarjian, Charles Sawyers, Andreas Hochhaus, et al.
Cancers|February 15, 2022
The Association between Patient Characteristics and the Efficacy and Safety of Selinexor in Diffuse Large B-Cell Lymphoma in the SADAL StudyJosée M Zijlstra, George Follows, Rene-Olivier Casasnovas, et al.
Clinical Lymphoma, Myeloma & Leukemia|January 26, 2022
Effect of Prior Therapy and Disease Refractoriness on the Efficacy and Safety of Oral Selinexor in Patients with Diffuse Large B-cell Lymphoma (DLBCL): A Post-hoc Analysis of the SADAL StudyMichael Schuster, Josée Zijlstra, Rene-Olivier Casasnovas, et al.
BMC Cancer|October 18, 2025
Digital and AI-assisted multimodal supportive care, combining physical activity, nutrition, and pain management during chemotherapy for advanced pancreatic cancer patients: study protocol of the European multicenter randomized controlled trial of the RELEVIUM projectBarlo Hillen, Gabrielle Oestreicher, Lisa Schwab, et al.
Clinical Lymphoma, Myeloma & Leukemia|September 8, 2021
Comparison of the Effectiveness and Safety of the Oral Selective Inhibitor of Nuclear Export, Selinexor, in Diffuse Large B Cell Lymphoma SubtypesRene-Olivier Casasnovas, George Follows, Josee M Zijlstra, et al.
Journal of Hematology & Oncology|July 17, 2021
Survival among patients with relapsed/refractory diffuse large B cell lymphoma treated with single-agent selinexor in the SADAL studyMarie Maerevoet, Josee M Zijlstra, George Follows, et al.
Journal of Critical Care|August 10, 2020
Therapy limitation in octogenarians in German intensive care units is associated with a longer length of stay and increased 30 days mortality: A prospective multicenter studyRaphael Romano Bruno, Bernhard Wernly, Michael Beil, et al.
Nature Metabolism|February 4, 2021
SARS-CoV-2 infects and replicates in cells of the human endocrine and exocrine pancreasJanis A Müller, Rüdiger Groß, Carina Conzelmann, et al.
Blood|May 30, 2023
Biallelic NFATC1 mutations cause an inborn error of immunity with impaired CD8+ T-cell function and perturbed glycolysisSevgi Kostel Bal, Sarah Giuliani, Jana Block, et al.
Pageof 15

Showing results (121-130 of 145) with videos related to

Sort By:
Pageof 15
Journal of Clinical Anesthesia|August 14, 2025
Removal of EpCAM-positive tumor cells during intraoperative blood salvage- A pivotal multicenter clinical study (REMOVE)Patrick Meybohm, Suma Choorapoikayil, Sebastian Zinn, et al.
The New England Journal of Medicine|March 1, 2002
Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemiaHagop Kantarjian, Charles Sawyers, Andreas Hochhaus, et al.
Cancers|February 15, 2022
The Association between Patient Characteristics and the Efficacy and Safety of Selinexor in Diffuse Large B-Cell Lymphoma in the SADAL StudyJosée M Zijlstra, George Follows, Rene-Olivier Casasnovas, et al.
Clinical Lymphoma, Myeloma & Leukemia|January 26, 2022
Effect of Prior Therapy and Disease Refractoriness on the Efficacy and Safety of Oral Selinexor in Patients with Diffuse Large B-cell Lymphoma (DLBCL): A Post-hoc Analysis of the SADAL StudyMichael Schuster, Josée Zijlstra, Rene-Olivier Casasnovas, et al.
BMC Cancer|October 18, 2025
Digital and AI-assisted multimodal supportive care, combining physical activity, nutrition, and pain management during chemotherapy for advanced pancreatic cancer patients: study protocol of the European multicenter randomized controlled trial of the RELEVIUM projectBarlo Hillen, Gabrielle Oestreicher, Lisa Schwab, et al.
Clinical Lymphoma, Myeloma & Leukemia|September 8, 2021
Comparison of the Effectiveness and Safety of the Oral Selective Inhibitor of Nuclear Export, Selinexor, in Diffuse Large B Cell Lymphoma SubtypesRene-Olivier Casasnovas, George Follows, Josee M Zijlstra, et al.
Journal of Hematology & Oncology|July 17, 2021
Survival among patients with relapsed/refractory diffuse large B cell lymphoma treated with single-agent selinexor in the SADAL studyMarie Maerevoet, Josee M Zijlstra, George Follows, et al.
Journal of Critical Care|August 10, 2020
Therapy limitation in octogenarians in German intensive care units is associated with a longer length of stay and increased 30 days mortality: A prospective multicenter studyRaphael Romano Bruno, Bernhard Wernly, Michael Beil, et al.
Nature Metabolism|February 4, 2021
SARS-CoV-2 infects and replicates in cells of the human endocrine and exocrine pancreasJanis A Müller, Rüdiger Groß, Carina Conzelmann, et al.
Blood|May 30, 2023
Biallelic NFATC1 mutations cause an inborn error of immunity with impaired CD8+ T-cell function and perturbed glycolysisSevgi Kostel Bal, Sarah Giuliani, Jana Block, et al.
Pageof 15